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Abstract
Background: Activation-induced induction of transcription factor NFκB in T lymphocytes is
regulated by its inhibitor IκBα. NFκB activation has been demonstrated to occur either by
phosphorylation on serine residues 32 and 36 of the inhibitor, IκBα, followed by ubiquitination and
degradation of the inhibitor by the 26S proteasome, or by a proteasome-independent mechanism
involving tyrosine phosphorylation, but not degradation. However, the mechanism underlying
constitutive regulation of the levels of the inhibitor, IκB, in primary human T lymphocytes, remains
to be fully delineated.
Results:  We demonstrate here, the involvement of a proteasome-independent pathway for
constitutive regulation of IκBα levels in primary human T lymphocytes. Pretreatment with a cell
permeable calpain inhibitor, E64D, but not with a proteasome specific inhibitor, lactacystin, blocks
stimulus-independent IκBα degradation in primary human T cells. However, E64D pre-treatment
fails to impact on IκBα levels following stimulation with either TNFα or pervanadate. Other
isoforms of the inhibitor, IκBβ, and IκBγ, appear not to be subject to a similar ligand-independent
regulation. Unlike the previously reported decline in ligand-induced degradation of IκBα in T cells
from the elderly, constitutive degradation does not exhibit an age-associated decline,
demonstrating proteasome-independent regulation of the activity.
Conclusion: Our studies support a role for an E64D sensitive protease in regulating constitutive
levels of IκBα in T cells, independent of the involvement of the 26S proteasome, and suggests a
biological role for constitutive degradation of IκBα in T cells.
Background
Transcription factor NFκB exists as homo-or-hetero-
dimeric complexes, consisting of the Rel family of pro-
teins [1]. These dimers operate as transcriptional regula-
tors essential for a variety of cellular processes ranging
from cell cycle progression to immune response gene
induction [2]. In human T lymphocytes, like most other
cells, NFκB exists in the cytoplasm coupled to its inhibitor
IκBα or IκBβ, predominant members of IκB family of pro-
teins [3]. A high affinity for RelA and c-Rel molecules ena-
bles these inhibitory proteins to associate with and thus
restrict nuclear localization of the NFκB molecules. Most
stimuli responsible for NFκB induction have been dem-
onstrated to either invoke serine phosphorylation of the
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inhibitory proteins followed by ubiquitination and degra-
dation via the 26S proteasome pathway, or involve the
activation of tyrosine phosphorylation, as in the case of
oxidative stress mediated stimuli, which is independent of
proteasomal degradation mechanism [4,5]. While stimu-
lation-induced modification of IκB has been studied
extensively, little is known about the constitutive regula-
tion of IκB protein in T cells under resting conditions.
Recent studies in B cell lines have demonstrated that IκBα,
but not IκBβ, is constitutively degraded and is important
for the induction of constitutive NFκB activity [6,7]. These
studies indicate that constitutive degradation of IκB is
mediated by a proteasome independent pathway. Studies
also suggest that a calcium-dependent protease, calpain,
may be important in regulating levels of IκBα [8-10].
These studies prompted us to investigate whether a similar
regulation of "constitutive" i.e., stimulus-independent
levels of IκBα occurs in primary T lymphocytes. Unlike B
cells, NFκB induction and IκB regulation reported in T
cells is clearly mediated by exogenous activating stimuli,
with little or no constitutive nuclear NFκB present under
basal condition.
Further, as NFκB regulation is significantly altered during
aging in human T cells, we examined whether abnormal
constitutive regulation may underlie lowered activation-
mediated induction. Employing primary T cells obtained
from human donors, we evaluated whether aging affects
the regulation of constitutive levels of IκBα. We hypothe-
Effect of age on constitutive degradation of IκBβ Figure 2
Effect of age on constitutive degradation of IκBβ. T 
cells obtained from young and elderly donors were either 
treated with E64D (+), 50 µM, or left untreated (-) for 45 
minutes. At the end of incubation, cells were washed and cell 
lysates prepared. Lysates, equalized for protein, were 
resolved using SDS-PAGE, followed by electroblotting. 
Resolved proteins were detected using specific antibody to 
IκBβ and ECL. Representative data from one donor pair are 
presented (A). Values obtained from a minimum of 4 donor 
pairs following densitometric scanning, are presented as 
mean integrated density units ± S.D.(B).
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Effect of treatment with E64D on constitutive levels of IκBα  in T cells from young and elderly donors Figure 1
Effect of treatment with E64D on constitutive levels 
of IκBα in T cells from young and elderly donors. T 
cells obtained from young and elderly donors were either 
treated with E64D (+), 50 µM, or left untreated (-) for 45 
minutes. At the end of incubation, cells were washed and cell 
lysates prepared. Lysates, equalized for protein, were 
resolved using SDS-PAGE, followed by electroblotting. 
Resolved proteins were detected using specific antibody to 
IκBα and ECL. Representative data from one donor pair are 
presented (A). Values obtained from a minimum of 4 donor 
pairs following densitometric scanning, are presented as 
mean integrated density units ± S.D.(B); ** indicates statisti-
cal difference from untreated controls.
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sized that, as constitutive levels of IκBα were relatively
unaffected by age in primary T cells, this may reflect min-
imal effect of age on calpain activity in T cells. We now
report that E64D sensitive protease, calpain, is indeed
responsible for regulating constitutive levels of IκBα, but
not IκBβ or IκBγ, in human T cells. Further, calcium-iono-
phore mediated increase in calpain activity induced in T
cells from young donors showed consistently higher activ-
ity at early time points after activation, when compared to
the elderly. However, total calpain activity measured at
the end of 60 minutes demonstrated no significant mod-
ulation based on the age of the donor. Thus, while the
kinetics of calpain activation appears to be altered in T
cells from the elderly, cumulative activity over a period of
time remains unaffected. Additionally, we demonstrate
that aging does not significantly affect stimulus-independ-
ent degradation of IκBα mediated by calpain, demonstrat-
ing proteasome-independent regulation. Thus, the
calpain system is involved in the constitutive regulation of
IκBα, and hence the NFκB signaling pathway, under rest-
ing conditions, in primary human T lymphocytes.
Results
Treatment with a cell permeable cysteine protease 
inhibitor, E64D, inhibits constitutive degradation of IκBα 
but not IκBβ or IκBγ in T lymphocytes from young and 
elderly donors
We examined the effect of a cell permeable cysteine pro-
tease inhibitor, E64D, on the basal levels of IκBα, IκBβ
and IκBγ, inhibitors of the ubiquitous transcription factor
NFκB. Employing primary T cells and western blotting
using antibody specific to the inhibitor isoforms, we now
demonstrate that constitutive levels of IκBα, but not IκBβ
or IκBγ are modulated by pretreatment with E64D. Results
presented in fig. 1, demonstrate that pretreatment with
E64D significantly inhibits constitutive degradation of
Effect of E64D on stimulus-dependent modification of IκBα  (Western Blots) Figure 4
Effect of E64D on stimulus-dependent modification 
of IκBα (Western Blots). T cells obtained from young and 
elderly donors were either left untreated or treated with 
E64D (50 µM) for 45 min. At the end of incubation cells 
were stimulated with 100 µM pervanadate or TNFα (10 ng/
ml) for 10, 20 or 30 min. Cell lysates were prepared and 
resolved by SDS-PAGE, using equal amounts of protein (30 
µg / lane). Resolved proteins were transferred to nitrocellu-
lose membrane and Western blotted with antibody to IκBα 
and detected using ECL. Representative results obtained 
from one donor pair are presented. Arrows represent IκBα 
specific bands detected and used in the analyses.
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Effect of age on constitutive degradation of IκBγ Figure 3
Effect of age on constitutive degradation of IκBγ. T 
cells obtained from young and elderly donors were either 
treated with E64D (+), 50 µM, or left untreated (-) for 45 
minutes. At the end of incubation, cells were washed and cell 
lysates prepared. Lysates, equalized for protein, were 
resolved using SDS-PAGE, followed by electroblotting. 
Resolved proteins were detected using specific antibody to 
IκBγ and ECL. Representative data from one donor pair are 
presented (A). Values obtained from a minimum of 4 donor 
pairs following densitometric scanning, are presented as 
mean integrated density units ± S.D.(B).
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IκBα with little or no effect on either IκBβ (fig. 2) or IκBγ
(fig. 3). Levels of IκBα before treatment with E64D are sig-
nificantly lower, than that observed following treatment,
indicating inhibition of degradation.
As IκBα degradation induced by exogenous signals has
been reported to be differentially regulated during aging
[8,9], we next assessed the effect of treatment with E64D
on IκB-α in T cells obtained from young and elderly
donors. Results presented in fig. 1, demonstrate that, irre-
spective of the age of the T cell donor, E64D pretreatment
significantly protected IκBα levels from constitutive deg-
radation, and had little impact on isoforms, IκBβ (fig. 2)
and IκBγ (fig. 3). Thus, aging does not influence cysteine
protease-sensitive constitutive degradation of IκBα in T
cells.
Treatment with proteasome inhibitor, Lactacystin, fails to  affect constitutive levels of IκBα in human T cells Figure 6
Treatment with proteasome inhibitor, Lactacystin, 
fails to affect constitutive levels of IκBα in human T 
cells. T cells obtained from young and elderly donors were 
either left untreated (-) or treated with lactacystin (5 µM) for 
2 h to inhibit the proteasome. At the end of incubation cells 
were washed and lysates were prepared as described. Equal 
amounts of protein from cell lysates were resolved using 
SDS-PAGE and electroblotted. Resolved IκBα was detected 
using antibody to IκBα and ECL. To ensure equal protein 
loading, blots were stripped and reprobed with β-actin. Rep-
resentative data from one donor pair are presented (A). As a 
positive control for lactacystin, T cells from young and eld-
erly donors were either pretreated with Lactacystin (5 µM, 2 
h) and then activated with TNFα for 10 min (L+T) or acti-
vated with TNFα without lactacystin pretreatment (T). US 
represent untreated T cells. Cell lysates were resolved using 
SDS-PAGE and IκBα detected as indicated above (B).
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Effect of E64D on stimulus-dependent modification of IκBα  (Integrated Densities) Figure 5
Effect of E64D on stimulus-dependent modification 
of IκBα (Integrated Densities). T cells obtained from 
young and elderly donors were either left untreated or 
treated with E64D (50 µM) for 45 min. At the end of incuba-
tion cells were stimulated with 100 µM pervanadate or 
TNFα (10 ng/ml) for 10, 20 or 30 min. Cell lysates were pre-
pared and resolved by SDS-PAGE, using equal amounts of 
protein (30 µg / lane). Resolved proteins were transferred to 
nitrocellulose membrane and Western blotted with antibody 
to IκBα and detected using ECL. Mean integrated densities of 
IκBα specific bands obtained from a minimum of 4 donor 
pairs were used to determine fold change when compared to 
their respective controls and are presented as Mean (fold-
change) ± S.D. [TNF-α (A); Pervanadate (B)].
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Inhibition of cysteine protease activity by E64D does not 
affect TNFα-induced degradation of IκBα in T cells
Treatment of T cells by activating stimuli such as, anti-
CD3 or TNFα, have been demonstrated to induce tran-
scription factor NFκB activation by a signal-induced, pro-
teasome-mediated degradation of the inhibitor IκBα. To
determine whether such signal-induced degradation of
IκBα was subjected to regulation by cysteine proteases, we
next examined the role of E64D on activation-induced
levels of IκBα. Results depicted in fig. 4 and 5A, clearly
demonstrate that activation of T cells with TNFα induces
degradation of IκB-α, irrespective of treatment with E64D.
This indicates that E64D sensitive protease does not mod-
ulate or impact on activation-induced, proteasome-
dependent degradation of IκBα. It should be noted that a
slower mobility IκBα band appears at later time-points
(20 and 30 min.) in TNF activated cells from the elderly.
We believe that this represents modified IκBα. Future
experiments will determine the precise nature of this
modification. As proteasome dependent degradation of
IκBα is clearly differentially regulated in T cells from
young and elderly donors, we next examined, whether
E64D mediated inhibition of constitutive levels impact
differentially on the induced degradation of IκBα in T
cells from the elderly. Results presented in fig. 5A, demon-
strate that pre-treatment with E64D failed to influence
activation-induced degradation of IκBα. Thus, irrespective
of the age of the donor, treatment with E64D failed to
modulate activation-induced degradation of IκBα.
Pretreatment with E64D does not interfere with 
activation-induced modification mediated by pervanadate 
treatment in T cells
As a next step in the analyses, we examined the effect of
pretreatment with E64D on modes of activation that does
not involve signal-induced degradation of IκBα, such as
those mediated by pervanadate. Similar to the observa-
tion with TNFα, pretreatment with E64D failed to impact
on activation-induced IκBα modification in cells pre-
treated with pervanadate, irrespective of the age of the
donor (fig. 4 and 5B). It is important to note that IκBα in
cells treated with pervanadate clearly demonstrate a
slower mobility band representing tyrosine-phosphor-
ylated IκBα. Thus, irrespective of the activation stimuli
(TNFa or Pervanadate), E64D appeared not to impact on
Basal Calpain activity in T cells obtained from young and eld- erly donors Figure 8
Basal Calpain activity in T cells obtained from young 
and elderly donors. T cells obtained from young and eld-
erly donors were adjusted to 2.5 × 105 cells /ml. Calpain 
activity was measured using a fluorogenic substrate Boc-Met-
AMC at 380 nm exc and 460 nm emm using a fluorometer. Spe-
cific activity was determined in the presence of calpain inhibi-
tor E64D. Values represent calpain specific activity and 
represent Mean fluorescence intensity ± S.D of data obtained 
from 4 independent experiments.
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Pretreatment with E64D inhibits calpain-mediated degrada- tion of IκBα in T cell lysates Figure 7
Pretreatment with E64D inhibits calpain-mediated 
degradation of IκBα in T cell lysates. T cell lysates 
obtained from young donors were pooled and 50 µg protein 
was incubated with 0.01 U purified calpain. The mixture was 
incubated at 37°C for 15 min. At the end of incubation sam-
ples were denatured and resolved using SDS-PAGE. IκBα 
was detected usingspecific antibody and ECL (A). Values 
obtained from a minimum of 4 donor pairs following densito-
metric scanning, are presented as mean integrated density 
units ± S.D. (B). * indicates significant degradation (p < 0.05).
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the activation-induced modulation of IκBα. NFκB
dependent luciferase activity was also assayed following
pervanadate treatment, in the presence or absence of
E64D. In keeping with the data obtained with IκBα, E64D
pretreatment, failed to impact on NFκB dependent luci-
ferase activity, (data not shown).
Treatment of T cells with proteasome inhibitor, 
Lactacystin, does not influence constitutive IκB-α levels, 
unlike that mediated by E64D
As IκB-α is constitutively degraded by E64D sensitive
cysteine protease, we next assessed whether treatment
with a proteasome inhibitor also interfered with this basal
degradation. Results presented in fig. 6A, clearly demon-
strate that pretreatment with lactacystin, a proteasome
specific inhibitor, failed to influence basal levels of IκBα.
Thus suggesting that basal or constitutive regulation of
IκB-α is not dependent on the proteasome. To ensure that
lactacystin did inhibit proteasome at the dose employed,
i.e. positive control, T cells from young and elderly donors
were either pretreated with lactacystin or left untreated.
These cells were then subjected to treatment with TNFa. As
seen in fig. 6B, TNFa treatment in the young induced deg-
radation of IκBα, when compared to untreated controls.
Pretreatment with lactacystin and then TNFα (L+T),
inhibited TNFa mediated degradation. As reported previ-
ously, lactacystin is only minimally effective in T cells
from the elderly.
Treatment of T cell lysates with purified calpain, mimics 
constitutive degradation of IκBα
As E64D pretreatment specifically inhibited basal degra-
dation of IκBα, implicating a role for cysteine proteases
such as calpain in regulating the constitutive levels of
IκBα, we tested for a direct role for calpain by treating
cytosolic lysates obtained from T cells with a purified
preparation of calpain in an in vitro assay. T cell lysates
equalized for protein from young donors were pooled
and subjected to lysis in the presence of purified calpain,
as indicated. Degradation of IκBα was determined by
measuring the detectable levels of IκBα by SDS-PAGE and
western blotting using antibody to IκBα. Results pre-
sented in fig. 7, show that upon exposure to 0.01 U of cal-
pain, lysates from T cells demonstrate lowered levels of
IκBα, indicating calpain-mediated degradation, which is
inhibited by pretreatment with E64D.
Kinetics of induction of calpain activity following calcium 
ionophore treatment, is modulated by age, but has no 
impact on overall effective calpain activity in T cells
To assess the effect of age on calpain activity, we obtained
T cells from young and elderly healthy volunteers and
examined them for endogenous calpain activity. As dem-
onstrated in fig. 8, calpain specific protease hydrolyzing
activity appeared to be slightly higher at time 0 in T cells
from young donors; however, calcium ionophore induced
increase in calpain activity was not significantly different
between T cells from young and elderly donors. In fact,
total hydrolyzing activity measured at the end of 60 min-
utes was not statistically different between cells obtained
from the two age groups. Therefore, effective calpain activ-
ity remained unaffected by age of the T cell donor.
Discussion
Calpain system has been demonstrated to be the main
protease involved in constitutive degradation of IκBα [7-
9]. Delineation of the exact region of IκBα necessary for
degradation by calpain resulted in the identification of the
C-terminal 39 amino acid sequence containing the PEST
sequence to be critical for degradation in vitro by Shum-
way and Miyamoto [6]. However, their studies, demon-
strated that calpain was not responsible for the
degradation of IκBα in primary B cells [6]. Unlike B cells,
that express constitutive nuclear NFκB, significant nuclear
expression of NFκB in T cells occurs predominantly fol-
lowing stimulus-induced activation. Few studies, to date,
have delved into constitutive regulation of NFκB in resting
T cells. In our current studies, employing E64D, we dem-
onstrate specificity of constitutive degradation of IκBα
mediated by calpain in human primary T lymphocytes.
The inhibition of this degradation in the presence of
E64D, a cell permeable, cysteine protease inhibitor, sup-
ports the potential involvement of calpain activity in this
process. Given the central role of NFκB in cell survival and
signaling [11], constitutive degradation of the inhibitor
IκBα is vital in understanding steady state kinetics of T cell
regulation in the context of immune activation.
Our studies also demonstrate that degradation of IκBα
under resting condition is refractory to proteasome inhib-
itor, Lactacystin, but not to calpain inhibitor, E64D.
Therefore, unlike that reported for activation-induced
degradation [12], constitutive levels of IκBα appear not to
be subject to proteosomal regulation. This is particularly
important given that our previous findings clearly showed
that inducible degradation of IκBα is subject to an "age-
effect" due to the inhibitory action of aging on proteas-
ome- associated proteolytic activity [13,14].
Calpain-dependent degradation of IκBα has been demon-
strated to occur in other cell types, which are refractory to
proteasome activity [11]. Thus, it appears, that the degra-
dation of IκBα can occur through two mutually exclusive
pathways, dependent on the state of the cells, i.e., resting
versus activated. Calpain system plays a role in constitu-
tive, but not induced IκBα degradation, while proteasome
degradation dictates induced levels in T cells [6,12]. Cal-
pain activity has been demonstrated to be involved in the
degradation of IκBα under certain conditions of viral
infection [8]. It is therefore likely that this ability of con-Immunity & Ageing 2005, 2:15 http://www.immunityageing.com/content/2/1/15
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stitutive degradation may be exploited by certain patho-
gens.
Unlike the most predominant inhibitor IκBα; IκBβ and
IκBγ isoforms, appear not to be susceptible to this calpain-
mediated degradation. Recent elegant experiments by
Miyamoto et al implicate similar degradation kinetics for
IκBα isoform in B cell lines [6]. Drawing upon the signif-
icance of such degradation events in the constitutive
induction of NFκB in B cells, the role for constitutive reg-
ulation of NFκB by the calpain pathway in primary T cells
was examined here. Results from these experiments
clearly provide a biological basis for stimulus-independ-
ent degradation and its importance in the maintenance of
NFκB in cell survival, which is not evident, unless chal-
lenged by stimuli capable of inducing apoptosis (data not
shown).
Our studies on the effect of advancing age on constitutive
degradation of IκBα, clearly implicate absence of any
effect of donor age on the maintenance of E64D protease
sensitive/calpain activity responsible for this degradation.
Experiments conducted to determine the impact of aging
on calpain activity clearly indicate that the effective activ-
ity is unaltered during aging. This is also reflected in the
levels of IκBα in resting T cells from young and elderly
donors, which are unaffected by age. Thus, despite loss in
proteasome activity accompanying aging, calpain-medi-
ated degradation of IκBα remains unaltered, demonstrat-
ing little or no role for the proteasomal regulation in
calpain-mediated pathway that regulates IκBα levels. This
observation is in keeping with earlier reports from our
laboratory that demonstrated minimal effect of age on
overall cellular proteolytic activity, especially, T cell chy-
motryptic activity [15]. It is also interesting to note that
reports on calpain activity as a function of advancing age
have been conflicting, with some demonstrating
increased activity, [16,17] and others, decreased activity
[18,19], however, these studies either used other cell
types, employed exogenous substrates or cell lysates for
the evaluation of the activity. Using a fluorogenic model
substrate that is cell permeable, we now demonstrate that,
ionomycin-inducible specific calpain activity, inhibitable
by E64D, is unaffected; however, proteolytic activity
observed in T cell lysates appeared to follow different
kinetics in cells from the young than those observed in the
elderly. Importantly, while 90% of the activity in cells
from the young was clearly inhibitable by treatment with
E64D, only 50% of the activity was inhibitable in cells
from the elderly (data not shown).
While constitutive degradation of IκBα is clearly regulated
by E64D sensitive calpain in T cells, activation-induced
degradation, appears unaffected by pretreatment with
E64D. Similarly, while activation-induced degradation of
IκBα is sensitive to proteasome inhibition, constitutive
degradation is unaffected by pretreatment with lactacys-
tin, a proteasome inhibitor. Clearly, susceptibility of IκBα
to degradation is not only dependent on the state of acti-
vation but also on the specificity of the protease. The
physiologic significance of the degradation of the inhibi-
tor clearly dictates induction of NFκB levels, and thus
anti-apoptotic or survival ability, under uninduced condi-
tions. Thus, regulation of IκBα levels in basal state of a cell
is crucial and sets the stage for activation-induced survival
signals. These results also indicate that the calpain path-
way works independently of phosphorylation, since nei-
ther TNF nor pervanadate that induce serine and tyrosine
phosphorylation, respectively, were affected by the inhib-
itor. Further, while proteasome dependent activation-
induced degradation pathway, as well as proteasome
pathway has been demonstrated to be compromised in T
cells during aging, calpain activity clearly appears to be
still functional, and is minimally affected by advancing
age.
Conclusion
In summary, we have demonstrated that basal levels of
IκBα, but not IκBβ or IκBγ are subject to regulation by
E64D sensitive protease, and can be mimicked by pre-
treatment with calpain. The regulation of IκBα levels by
cysteine protease appears to have no effect on activation-
induced IκBα or on other isoforms of IκB, irrespective of
the stimuli employed. Additionally, it appears that inter-
ference with this decrease in basal degradation of IκBα
does not impact on cell survival under resting conditions.
Methods
Materials
Fluorochrome labeled anti-CD3, and FITC- and PE-
labeled isotype controls were obtained from Sigma Chem-
ical Co. (St. Louis, MO). Anti IgG coupled to horseradish
peroxidase was obtained from BD-Transduction Labora-
tories (Lexington, KY). All other antibodies were from
Santa Cruz Biotech (Carlsbad,CA). Enhanced Chemi-
luminescence reagents were from Amersham (Arlington
Heights, IL). All fine chemicals unless otherwise men-
tioned were obtained from Sigma Chemical Company,
(St. Louis, MO.), Electrophoresis supplies and Molecular
weight standards were from BioRad (Richmond, CA.).
E64D and lactacystin were from Calbiochem (CA). Sub-
strate for Calpain was from Molecular probes, (Eugene,
OR).
Human subjects
Blood was obtained from healthy individuals living in the
community. Young donors were between 21 and 30 years
and old donors were between 65 and 85 years of age. A
minimum of at least four donor pairs were used in each
experiment. Both young and elderly donors were in goodImmunity & Ageing 2005, 2:15 http://www.immunityageing.com/content/2/1/15
Page 8 of 9
(page number not for citation purposes)
physical and mental health, had no apparent illness as
suggested by an elaborate screening history and were not
on any medication directly impacting the immune system
during the course of this study.
T Lymphocyte Isolation
Peripheral blood was obtained and T cells were purified
and maintained in RPMI 1640 culture medium as previ-
ously described (20). Magnetic sorting by negative selec-
tion was used to isolate CD3+ T cells. Purity of the isolated
T cells was determined by flow cytometry using anti-CD3
conjugated to FITC. Populations were 90–95% pure.
Treatment of T cells (20 × 106cells/ml) with pervanadate
(100 µM, freshly prepared before use) was carried out for
indicated times at 37°C, before cell lysates were prepared.
For experiments involving the use of inhibitor, cells were
treated with E64D at 50 µM for 45 minutes.
Western blotting
Cytosolic extracts for Western blotting were prepared by
homogenization of cells in lysis buffer (1 mM Hepes, 10
mM KCl, 1.5 mM MgCl2, and 1 mM sodium orthovanad-
ate, and 0.5% NP-40) (20). The following reagents were
added to all buffers prior to their use: 0.5 mM dithiothre-
itol (DTT), 0.5 mM phenylmethylsulfonyl fluoride
(PMSF), and 10 µg/ml each of aprotinin, leupeptin, and
soybean trypsin inhibitor. Protein content of cytosolic
extracts was determined using BioRad protein assay. Cell
lysates equalized for protein (40 µg) were resolved by
SDS-polyacrylamide gel electrophoresis (PAGE), trans-
ferred to nitrocellulose, immuno-blotted with specific
antibody/s, and detected using anti-IgG coupled to horse-
radish peroxidase followed by Enhanced Chemi-lumines-
cence (ECL). Where possible samples from young and
elderly donors were resolved on the same gel, but in
experiments where different treatments were analyzed,
samples from young and the elderly were resolved on dif-
ferent gels, but were run simultaneously, to avoid inter
and intra experimental variability. Resolution of samples
on different gels did not influence the outcome of the
results.
Calpain activity assays
Using a cell permeable fluorescent substrate Boc-Met-
AMC, calpain activity within live cells was measured using
a spectrofluorometer. Fluorescence was measured in cell
suspension (2.5 × 105cells/ml) following the addition of
fluorophore, using the LS-50 model, Perkin-Elmer Spec-
trofluorometer. The fluorometer was equipped with a
magnetic stirrer and warmed with recirculating water at
37°C using a pump. Fluorescence was measured using
excitation and emission wavelengths of 380 and 460 nm,
respectively. Values were obtained using a time drive
mode, for up to 60 minutes.
Statistical analyses
Data were analyzed using student's t-test. Differences were
considered significant, if p < 0.05.
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